Navigation Links
Are Commercial Genetic Tests Worth Taking?
Date:10/14/2009

Experts cautious about validity, usefulness of some on the market

WEDNESDAY, Oct. 14 (HealthDay News) -- Peter Orszag, the 40-year-old head of the White House Office of Management and Budget, is reported to drink so much tea, hot and iced, that he took a genetic test to see if his body could metabolize his voluminous intake of caffeine.

According to the results, his body is perfectly suited to the task, and Orszag can easily go about his busy day, according to published reports.

Like Orszag, droves of people are flocking to get genetic tests -- which are now marketed direct-to-consumer -- ranging from the $179 CaffeineGen to assess caffeine metabolism to those that claim to gauge risk for Alzheimer's disease. There's also a $79 HomeDNA Home Paternity Testing System that includes, for an additional $25, lab services for the "alleged" father and one child.

But whether or not the commercially available genetic tests currently entering the market actually provide any useful information is another question.

According to Dr. Muin J. Khoury, director of the Office of Public Health Genomics at the U.S. Centers for Disease Control and Prevention, some 1,800 to 2,000 genetic tests have been developed, most of which are relevant only to rare genetic conditions that don't affect too many people.

"A growing number of these tests are suggested to be used to target interventions [pharmacogenetics], and to do early detection or susceptibility testing," Khoury said.

Khoury participated in a recent conference hosted by the National Academy of Sciences in Washington, D.C., that looked at direct-to-consumer marketing of genetic tests. Among other things, panelists discussed how valid and useful these tests are. Probably some will prove useful, and some will not, the experts said.

"With very few exceptions, we still have some big gaps in evidence," said Dr. Marc S. Williams, director of clinical genetics at the American College of Medical Genetics and director of Intermountain Healthcare, Clinical Genetics Institute, in Salt Lake City. "Do we really know if this works or not?"

"We don't know what they do to help people or hurt them," Khoury added.

Some are tried and true, such as those to detect the BRCA 1 and 2 genes, which heighten a woman's risk for breast and ovarian cancer, or specific tests to figure the risk for Lynch syndrome, a hereditary form of colon cancer.

But take the example of several much-hyped genetic tests to help determine what type or what dose of antidepressant would be effective for different individuals.

"Researchers have found that even clinically available tests that are supposed to inform someone about specific doses or specific medications use virtually no evidence. We don't even know what to do with the results of tests in terms of dosing, etcetera," Williams said. "People are promoting this test to choose which SSRI [selective serotonin reuptake inhibitor] they should use and at what dose with almost no evidence. We'd love to be able to predict which drug to use, but the evidence just isn't there to support that."

And results could be alarming to some people, said Sandra Soo-Jin Lee, senior research scholar and medical anthropologist at the Stanford University Center for Biomedical Ethics, although one recent study reported that people who discovered they had a higher risk for Alzheimer's through a genetic test were not psychologically distressed by the results.

Perhaps they kept in mind that genes are only one factor that determine risk. The environment also has a lot to do with it.

For instance, "there is a fairly robust history of research around genetic variations a population might express in terms of how they take up those chemicals. So, in terms of caffeine metabolism, there may be some individuals that are fast metabolizers of caffeine so it goes through their system fairly quickly," Lee said.

"But there may also be other things about that person and that person's environment that affect how they metabolize caffeine. For now, we just don't know what's what in terms of tests and results," she added.

"Right now, the direct-to-consumer genetic testing companies are working in an unregulated space. It's sort of a no man's land," Lee said. "But I think there are some indications that we are moving in a direction of creating some hopeful policies. One of the first steps is making sure all the stakeholders come together and discuss what would be helpful in terms of regulation. That not only means health-care providers and patients, but companies themselves."

Attempts by HealthDay to reach several makers of the tests for comment were unsuccessful.

More information

The U.S. National Library of Medicine has more on genetic testing.



SOURCES: Muin J. Khoury, M.D., Ph.D., director, Office of Public Health Genomics, U.S. Centers for Disease Control and Prevention, Atlanta; Marc S. Williams, M.D., director, clinical genetics, American College of Medical Genetics, and director, Intermountain Healthcare, Clinical Genetics Institute, Salt Lake City, Utah; Sandra Soo-Jin Lee, Ph.D., senior research scholar and medical anthropologist, Stanford University Center for Biomedical Ethics, Palo Alto, Calif.; March 27, 2009, The New York Times


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. First Commercial Text Messaging Smoking Cessation Service Marks One Year of Operation
2. bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
3. Arcxis Biotechnologies Announces Release of First Commercial Product for Molecular Analysis
4. Edifecs(TM) Provides Free Commercial-Off-The-Shelf (COTS) Solution for Medicare Administrative Contractors (MACs)
5. Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?
6. King Announces Commercial Availability of EMBEDA(TM)
7. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
8. 3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st
9. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
10. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
11. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... families and businesses of the Norwalk and Vermillion areas, celebrates the newest ... (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer recovery support ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, Hodges-Mace, ... and centralized benefits dashboard solving one of the top frustrations in employee benefits ... the first time, employees can access up-to-date information and account balances for all ...
(Date:3/23/2017)... ... March 23, 2017 , ... Hakim Unique Group ... technology company California Healthcom Group (CHG). , The HUG investment is a ... headquarters in California, CHG is a growing, internationally recognized healthcare management, technology, and ...
(Date:3/23/2017)... Scottsdale, AZ (PRWEB) , ... March 23, 2017 , ... ... helping people around the world to manage stress and anxiety. , “Buzzies change ... Serin, neuropsychologist, inventor and co-founder of Buzzies. , Since its launch date in December ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... a new solution that enables organizations to easily reprint customer invoices, bills, statements ... Server’ automates all of the steps needed to retrieve and print the documents ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017   Icertis , the leading ... the cloud, today announced an upgrade to the ... to improve clinical trials contract management. Built on ... the solution speeds up clinical trial contracting while ... (CRO). "The pharmaceutical industry is ...
(Date:3/23/2017)... March 23, 2017 A research report ... is expected to reach USD 7.2 billion by the end ... preparation is a procedure in which a sample is preserved ... most analytical procedures since the methods are often allowing repeated ... of the most shared procedures in the lab. In many ...
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma A/S ... TransCon technology to address significant unmet medical needs in ... a conference call and webcast on Monday, April 3 ... Society in Orlando, Florida , to ... candidates (TransCon Growth Hormone, TransCon PTH and TransCon CNP). ...
Breaking Medicine Technology: